...
首页> 外文期刊>Transplant infectious disease: an official journal of the Transplantation Society >Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis
【24h】

Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis

机译:微生物学记录的大剂量美法仑和自体干细胞移植治疗轻链淀粉样变性患者的感染

获取原文
获取原文并翻译 | 示例

摘要

Background: Immunoglobulin light chain (AL) amyloidosis can be treated with high-dose melphalan and autologous stem cell transplantation (HDM/SCT). Risk factors for infections may include hyposplenism, hypogammaglobulinemia, treatment-related neutropenia, melphalan-induced mucositis, and nosocomial exposures. Methods and design: A review of 493 patients with AL amyloidosis undergoing treatment with HDM/SCT from August 1994 to August 2009 was performed. The objectives were to determine the rate and types of infections following HDM/SCT, to identify factors associated with microbiologically documented infections, and to assess the contribution of infections to all-cause treatment-related mortality (TRM; defined as deaths within 100 days of SCT). Results: Microbiologically documented infections after HDM/SCT occurred in 24% (n = 119) of patients. TRM was 10% (n = 48) overall, and 21% (n = 25) in patients who had a documented infection. Thus, the relative risk of TRM in a patient with a documented infection was 3.42 (95% confidence interval [CI] 2.02-5.79). Infections were caused by gram-positive bacteria in 51%, anaerobic bacteria in 16%, gram-negative bacteria in 13%, and fungi in 9% of cases. Serum creatinine >2 mg/dL was associated with increased risk of post-SCT infection (38% vs. 21%, P = 0.0007) with an odds ratio of 2.27 (95% CI 1.40-3.68). No significant association for infection was found for age, gender, cardiac involvement, prior steroid therapy, dose of melphalan, multiorgan involvement, days to neutrophil engraftment, or dose of CD34 + cells infused. Conclusion: Serum creatinine >2 mg/dL is a risk factor for infections in patients with AL amyloidosis undergoing HDM/SCT. The relative risk of TRM in a patient with a documented infection was increased >3-fold. A broad spectrum of infections, similar to that in other SCT patients, is seen in this population in the early post-SCT period.
机译:背景:免疫球蛋白轻链(AL)淀粉样变性可以用大剂量美法仑和自体干细胞移植(HDM / SCT)治疗。感染的危险因素可能包括脾功能低下,低血球蛋白血症,与治疗有关的中性粒细胞减少,美法仑引起的粘膜炎和医院暴露。方法和设计:回顾性分析了1994年8月至2009年8月接受HDM / SCT治疗的493例AL淀粉样变性患者。目的是确定HDM / SCT后的感染率和类型,确定与微生物学记录的感染相关的因素,并评估感染对全因治疗相关死亡率(TRM;定义为在100天内死亡)的贡献。 SCT)。结果:24%(n = 119)的患者发生了HDM / SCT后的微生物学记录的感染。总体而言,TRM为10%(n = 48),而有记录的患者为21%(n = 25)。因此,有证据表明感染患者的TRM相对风险为3.42(95%置信区间[CI] 2.02-5.79)。感染是由51%的革兰氏阳性细菌,16%的厌氧细菌,13%的革兰氏阴性细菌和9%的真菌引起的。血清肌酐> 2 mg / dL与SCT后感染的风险增加有关(38%比21%,P = 0.0007),比值比为2.27(95%CI 1.40-3.68)。没有发现与感染,年龄,性别,心脏受累,先前的类固醇治疗,美法仑的剂量,多器官受累,嗜中性粒细胞植入的天数或注入的CD34 +细胞的剂量相关。结论:血清肌酐> 2 mg / dL是接受HDM / SCT的AL淀粉样变性患者感染的危险因素。感染患者的TRM相对风险增加了3倍以上。在SCT后早期,该人群中发现了与其他SCT患者相似的广泛感染。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号